about
PKC{epsilon}-dependent and -independent effects of taurolithocholate on PI3K/PKB pathway and taurocholate uptake in HuH-NTCP cell lineRole of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.cAMP-GEF cytoprotection by Src tyrosine kinase activation of phosphoinositide-3-kinase p110 beta/alpha in rat hepatocytesFucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease--a comprehensive review.The Cholangiocyte Glycocalyx Stabilizes the 'Biliary HCO3 Umbrella': An Integrated Line of Defense against Toxic Bile Acids.CD14 is associated with biliary stricture formation.A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.Biliary bicarbonate secretion constitutes a protective mechanism against bile acid-induced injury in man.Methanobactin reverses acute liver failure in a rat model of Wilson disease.A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.Physiological hypoxia prevents bile salt-induced apoptosis in human and rat hepatocytes.Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver.1,25-(OH)₂-vitamin D₃ prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model.Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activityPhosphatidylcholines as regulators of glucose and lipid homeostasis: promises and potential risksMultidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosisEffect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and healthPrimary biliary cirrhosisAntimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis-like disease in mouse modelsSoluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases
P50
Q33771718-21ADDCC8-FA42-4CD9-A548-70FEAE4327A6Q36693626-BCB5E5AD-F670-4DFE-A3EF-E6A2C5D28E5DQ37162455-75B3CA00-9A4F-4007-A283-40634D25B5D9Q38211812-14955749-B9FE-45D8-8C2F-139B8E5CF212Q38516765-927F0439-3B9A-4B53-AA84-5F6B1E88B191Q38896152-475D401F-FE70-42FB-8B6A-AF49780D86CFQ39471132-3925A298-4959-40DC-97C2-4A0DC8593745Q39521016-EAB0CE07-3849-4B5E-B822-819179CBE114Q42130897-8F86A0F2-9BE5-446C-8AE3-D2474E463375Q45040478-53AC8732-5316-4265-A09C-2F01D46FF978Q45775350-702A210F-7F11-4B93-B3AE-B4EC092F7736Q46516304-F07F1260-F40A-4C8A-BB6F-5B2060F84231Q50451196-6CB65B91-A35D-4D3B-8EEE-6D848F7148C1Q60897042-6B317B68-6A32-4294-A34E-6F753160E0BEQ82798296-96D5CF98-A0A0-47E6-873B-560AD1DA17AEQ83053876-B5F1EE34-33A1-4765-92EB-FA06A0C85BD4Q83637970-C27249FC-58B9-42E1-8D19-1040C2E4A448Q84230884-714C8E4D-0B28-4076-8793-B77FA186D467Q85893865-4AD568B0-BB5A-4C3C-8DF6-3C73F9B0FBF1Q87143832-F356FD2E-17ED-4BFD-A566-8EBE4C858A56
P50
description
Forscher
@de
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simon Hohenester
@ast
Simon Hohenester
@bar
Simon Hohenester
@de
Simon Hohenester
@en
Simon Hohenester
@es
Simon Hohenester
@fr
Simon Hohenester
@nl
type
label
Simon Hohenester
@ast
Simon Hohenester
@bar
Simon Hohenester
@de
Simon Hohenester
@en
Simon Hohenester
@es
Simon Hohenester
@fr
Simon Hohenester
@nl
prefLabel
Simon Hohenester
@ast
Simon Hohenester
@bar
Simon Hohenester
@de
Simon Hohenester
@en
Simon Hohenester
@es
Simon Hohenester
@fr
Simon Hohenester
@nl
P106
P21
P31
P496
0000-0002-9982-6317